A: Yes. Silicones are widely used in implantable devices, transdermal patches, and controlled release systems. Their flexibility, chemical inertness, and permeability allow for sustained release of active pharmaceutical ingredients (APIs), while maintaining long-term stability and patient safety.

A: Silico® silicone formulations are produced under strict quality controls including GMP, ISO standards. Purity is verified by testing for extractables/leachables, cytotoxicity, hemolysis, and biocompatibility per ISO 10993 / USP guidelines. Batch documentation and regulatory support are provided to ensure compliance.

A: Yes. Silicone fluids and resins provided by Silico® are designed for excellent thermal, chemical, and mechanical stability. They resist degradation under heat, disinfectants, varying pH, and exposure to moisture, ensuring product integrity in creams, gels, suspensions, and coated forms.

A: For injectable/parenteral use, key safety considerations include absence of particulate contaminants, sterility, non-pyrogenicity, and negligible migration of siloxanes. Using medical-grade, properly cured silicones with documented extractables/leachables profiles helps ensure safety.

A: Silicones are known for bio-durability: minimal degradation when exposed to physiological conditions, resistance to oxidation, UV, moisture, enzymatic breakdown, etc. They maintain functional integrity, flexibility, and biocompatibility over extended duration use.

A: Yes. Some cyclic volatile methyl siloxanes (e.g. D4, D5, D6) are under regulatory review in many regions for environmental persistence, bioaccumulation, or toxicity concerns. Silico® offers alternatives and keeps formulations aligned with evolving regulations (REACH, FDA, etc.).